CLINICAL STUDIES ON TA-058

Abstract

A clinical administration of TA-058 was conducted with five patients who were suffering from various infections.
To one patient who had infective endocarditis which was caused by S. faecals associated mitral insufficiency, drip injections of 1g of TA-058 for 1.5 hrs. three times a day were given for ten days. This treatment eradicated the causative organism, but did not normalize her body temperature. Abatement of fever and normalization of laboratory data were gained by drip injection of 2g of TA-058 three times a day. The maximum serum level of 2g of TA-058 was 123 μg/ml, and the minimum level before the next drip injection was 13.2μg/ml.
In other four patients TA-058 was used 1 g twice a day. Therapeutic effects of TA-058 were fair in one patient with pneumonia, and good in one with acute exacerbation of chronic bronchitis caused by S. pneumoniae.
In two patients with acute exacerbation of chronic pyelonephritis, effects of TA-058 were good in one caused by S. faecalis, and fair in one caused by E. coli. No side effects and abnormalities of laboratory data were found in any one case.